Although further studies on MDR1 function and its regulation by CDX2 are required to elucidate the complex drug resistance mechanism, our results demonstrate the potential of novel chemotherapy regimens based on CDX2 status and MDR1 expression in ovarian mucinous adenocarcinoma. The gene discussed is CDX2; the disease is ovarian mucinous adenocarcinoma.